Alnylam Added to Russell 3000 Index | GenomeWeb
NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals was added to the Russell 3000 and Russell 2000 after the markets closed on June 30, the company said today.
Alynlam said its inclusion in these indexes reflects an interest "in the potential of RNAi for therapeutic applications, and the promise of this technology," said John Maraganore, president and CEO of Alnylam Pharmaceuticals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Nature this week: genetic history of HIV in the US, and more.